Table 3.
Logistic Regression Analysis using protein concentration, before and after adjusting for covariates.
| Test | Unadjusted |
Adjusted |
|||
|---|---|---|---|---|---|
| Protein | OR | 95% CI | OR | 95% CI | |
| A. Discovery dataset | |||||
| T1D_NoC vs. ABN | IGFBP1 | 1.196 | (1.060–1.350) | 1.221 | (1.077–1.385) |
| IGFBP2 | 1.296 | (1.119–1.505) | 1.280 | (1.104–1.489) | |
| IGFBP3 | 0.929 | (0.823–1.049) | 0.929 | (0.821–1.049) | |
| IGFBP6 | 1.220 | (1.071–1.392) | 1.264 | (1.089–1.470) | |
| IGFBP7 | 0.762 | (0.670–0.864) | 0.754 | (0.661–0.857) | |
| 1Comp vs. ABN | IGFBP1 | 1.359 | (1.094–1.69) | 2.443 | (1.801–3.372) |
| IGFBP2 | 2.474 | (1.832–3.41) | 2.365 | (1.632–3.520) | |
| IGFBP3 | 0.568 | (0.449–0.714) | 0.478 | (0.357–0.636) | |
| IGFBP6 | 2.940 | (2.215–3.971) | 1.838 | (1.285–2.676) | |
| IGFBP7 | 1.024 | (0.802–1.319) | 0.794 | (0.590–1.069) | |
| 2Comp vs. ABN | IGFBP1 | 1.826 | (1.303–2.576) | 4.095 | (2.499–7.167) |
| IGFBP2 | 3.936 | (2.498–6.506) | 4.757 | (2.641–9.522) | |
| IGFBP3 | 0.627 | (0.450–0.889) | 0.523 | (0.339–0.811) | |
| IGFBP6 | 3.588 | (2.360–5.702) | 3.561 | (2.016–6.776) | |
| IGFBP7 | 1.183 | (0.796–1.803) | 1.011 | (0.630–1.668) | |
| 3Comp vs. ABN | IGFBP1 | 1.885 | (1.314–2.722) | 8.153 | (3.895–20.107) |
| IGFBP2 | 5.013 | (3.003–8.975) | 8.421 | (3.728–23.227) | |
| IGFBP3 | 0.724 | (0.508–1.065) | 0.668 | (0.412–1.071) | |
| IGFBP6 | 7.460 | (4.392–13.915) | 10.06 | (4.595–26.378) | |
| IGFBP7 | 2.047 | (1.316–3.20) | 1.833 | (1.064–3.323) | |
| B. Confirmation dataset | |||||
| T1D_NoC vs. ABN | IGFBP1 | 1.237 | (1.134–1.351) | 1.305 | (1.193–1.43) |
| IGFBP2 | 1.801 | (1.632–1.993) | 1.782 | (1.614–1.972) | |
| IGFBP3 | 0.905 | (0.825–0.990) | 0.915 | (0.834–1.001) | |
| IGFBP6 | 1.289 | (1.171–1.421) | 1.222 | (1.1–1.36) | |
| 1Comp vs. ABN | IGFBP1 | 1.427 | (1.198–1.712) | 2.283 | (1.824–2.895) |
| IGFBP2 | 3.151 | (2.568–3.906) | 3.444 | (2.716–4.432) | |
| IGFBP3 | 0.780 | (0.690–0.883) | 0.713 | (0.616–0.835) | |
| IGFBP6 | 2.881 | (2.293–3.654) | 1.725 | (1.324–2.283) | |
| 2Comp vs. ABN | IGFBP1 | 1.578 | (1.215–2.087) | 2.942 | (2.053–4.362) |
| IGFBP2 | 4.250 | (3.136–5.905) | 4.364 | (3.05–6.49) | |
| IGFBP3 | 0.875 | (0.738–1.109) | 0.751 | (0.581–1.075) | |
| IGFBP6 | 2.883 | (2.079–4.055) | 1.524 | (1.034–2.297) | |
| 3Comp vs. ABN | IGFBP1 | 2.000 | (1.468–2.804) | 3.985 | (2.607–6.408) |
| IGFBP2 | 5.144 | (3.630–7.551) | 6.396 | (4.044–10.844) | |
| IGFBP3 | 0.814 | (0.691–1.010) | 0.656 | (0.504–0.928) | |
| IGFBP6 | 6.408 | (4.312–9.947) | 3.694 | (2.3–6.159) | |
ABN, antibody negative controls; T1D_NoC, T1D no complications; 1Comp, T1D any complication; 2Comp, T1D with 2 complications; 3Comp, T1D with ≥3 complications.